GENENTECH, INC for GENENTECH INC
What was lobbied
6 issue areas, each in the filer's own words, with who lobbied on it and where.
Trade (domestic/foreign) TRD
Trade related issues;
| Lobbyist | Covered position, as disclosed |
|---|---|
| ELI KOGAN | Assistant Director |
Taxation/Internal Revenue Code TAX
Advocacy on maintaining the research and development tax credit; general tax issues and tax extenders (R&D tax credit) and tax treatment of foreign-owned US corporations.; S.2260, EXPIRE Act of 2014; H.R. 5771, Tax Increase Prevention Act of 2014;issues related to tax reform; Appropriations, R&D Tax credit; Tax: H.R. 5771 Tax Increase Prevention Act of 2014 (tax extenders) H.R. 2315 - 113th Congress (2013-2014) - Preserving Access to Orphan Drugs Act of 2013;
| Lobbyist | Covered position, as disclosed |
|---|---|
| ELI KOGAN | Assistant Director |
Health Issues HCR
Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicaid reimbursement for biotherapeutics, comparative effectiveness research, and FDA approval of follow-on biologics; Public Law 111-152, the Health Care and Education Reconciliation Act of 2010 - Implementation issues related to Medicare and Medicaid payment for biotherapeutics, the 340B program, and the Medicare drug benefit; Regulatory and legislative activities regarding 340B program; Issues relating to biologics; S. 959 "Pharmaceutical Compounding Quality and Accounting Act, HR 1416 "Cancer Patient Protection Act of 2013", S.957, "Drug Supply Chain Security", HR 1919 "Safeguarding America's Pharmaceuticals Act"; Issues related to the implementation of the Affordable Care Act of 2010; issues related to biosimilars; Issues concerning clinical trials; issues concerning drug compounding. Implementation of Patient Protection and Affordable Care Act. Federal Drug. Drug pricing under 340B program; Medical reimbursement - advocacy on behalf of maintaining ASP+6%, 340B Drug Discounting Program - education of Congress on unintended growth of program; Issues related to the implementation of the follow-on biologics provisions in P.L. 111-148 - "Patient Protection and Affordable Care Act"; PHA: Monitor Drug Safety and pedigree legislation. Monitor legislation and oversight on compounding pharmacies.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | Assistant Director |
| ANNA GRIFFIN | Sr. Director |
| EVAN MORRIS | VP Government affairs |
| KATHERINE RAAB | Director |
Medicare/Medicaid MMM
Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicard reimbursement for biotherapeutics. Meetings with House and Senate staff on coverage/payment issues related to cancer biotherapeutics. P.L. 112-240, the American Taxpayer Relief Act of 2012 - Medicare payment issues. H. Con. Res. 25, Establishing the budget for the United States Government for fiscal year 2014 and settin forth appropriate budgetary levels for fiscal years 2015 through 2023; and S. Con. Res. 8, An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 204, revising the appropriate budgetary levles for fiscal year 2013, and setting forth the appropriate budgetary levels for fiscal years 2015 through 2023 - Medicare Part B drug reimbursement issues. S.399, American Family Economic Protection Act of 2013 - sequestration issues affecting Medicare Part B drug reimbursement issues; S. 1871, the SGR Repeal and Medicar Beneficiary Access Act - Medicare physician payment and Part B drug reimburesement issues. H.R. 2810, the Medicare Patient Access and Quality Improvement Act - Medicare physician Payment and Part B drug reimburesement issues.spending. Public law 113-54- The Drug quality and Security Act - drug compounding and track trace issues.; Concerns regarding Medicare payment policies for Part B drugs. Issues related to the 340B Drug discount program; Payment policies for prescription drugs. Independent payment advisory board, H.R.2810, Medicare Patient Access and Quality Improvement Act of 2013; Medicare reimbursement issues; Medicare coverage and payment of Part B drugs and biologicals; 340B, Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B, dual eligiable demonstratins and relaed provisions Part B; Medicare reimbursement for physicians of The Affordable Care Act;
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | Assistant Director |
| ANNA GRIFFIN | Sr. Director |
| EVAN MORRIS | VP Government affairs |
Budget/Appropriations BUD
Issues related to FY2015 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations and H.R. 83, Consolidated and Further Continuing Appropriations; Following issues related to the budget and appropriations process FY 14 appropriations for FDA as well as the potential outcomes for negotiations on altering sequestration targets via legislation; Issues related to FDA & HHS program funding, FY15 Labor Health and Human Services, and Education, and Related Agencies, H.R. 4800, and FY 15 Agriculture, Rural Development, Food and Drug Administration and Related Agencies Appropriations Bills.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | Assistant Director |
| ANNA GRIFFIN | Sr. Director |
Pharmacy PHA
Public Law 112-144, the Food and Drug Administration Safety and Innovation Act - legislation related to reauthorization of user fees for prescription drug, medical device, and bilogics approval. All aspects. General issues and congressional oversight related to FDA approval and CMS coverage decisions regarding Avastin and and Lucentis. S. 959 - Pharmaceutical Quality, Security, and Accountability Act- legislation regardng pharmacy compounding and track and trace proposals. Public Law 113-67, Continuing Appropriations Resolution for 2014 - General public health spending. Public law 113-54- The Drug quality and drug compounding and track/trace issues
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | Asst. Director |
| ANNA GRIFFIN | Sr. Director |
| EVAN MORRIS | VP Government affairs |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.